| 摘要 |
Novel compounds that are inhibitors of one or most post-proline cleaving proteases, e.g. dipeptidyl peptidase IV, according to general formula (1). R<SUP>1 </SUP>is H or CN, X<SUP>1 </SUP>is O, S, CH<SUB>2</SUB>, CHF, CF<SUB>2</SUB>, CH(CH<SUB>3</SUB>), C(CH<SUB>3</SUB>)<SUB>2 </SUB>or CH(CN), and b is 1 or 2. G<SUP>1 </SUP>is H or a group according to the formula -CH<SUB>2</SUB>-X<SUP>2</SUP>-(CH<SUB>2</SUB>)<SUB>a</SUB>-G<SUP>3 </SUP>and G<SUP>2 </SUP>is H or a group according to the formula -CH<SUB>2</SUB>-(CH<SUB>2</SUB>9<SUB>a</SUB>-G<SUP>3</SUP>, provided that one of G<SUP>1 </SUP>and G<SUP>2 </SUP>is H and the other is not H. X<SUP>2 </SUP>is O, S, or CH<SUB>2</SUB>, and a is 0, 1 or 2, provided that when a is 1 then X<SUB>2 </SUB>is CH<SUB>2</SUB>. G<SUP>3 </SUP>is a group according to one of general formulae 2-4, where the variables have meaning given in the description. The compounds are useful in the treatment of i.a. type 2 diabetes and impaired glucose tolerance. |
